Craig Leonardi
Overview
Explore the profile of Craig Leonardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Puig L, Fujita H, Thaci D, Zheng M, Hernandez Daly A, Leonardi C, et al.
Dermatol Ther (Heidelb)
. 2024 Aug;
14(9):2331-2378.
PMID: 39088126
Generalized pustular psoriasis (GPP) is a rare, chronic and potentially life-threatening autoinflammatory skin disease characterized by widespread eruption of sterile pustules, with or without systemic inflammation. GPP can significantly reduce...
2.
Lebwohl M, Koo J, Leonardi C, Armstrong A, Rawnsley N, Goehring E, et al.
J Drugs Dermatol
. 2023 Apr;
22(4):419-422.
PMID: 37026879
Brodalumab is an interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe psoriasis in adults without response or with loss of response to other systemic therapies. Brodalumab carries a...
3.
Armstrong A, Fahrbach K, Leonardi C, Augustin M, Neupane B, Kazmierska P, et al.
Dermatol Ther (Heidelb)
. 2022 Jul;
12(8):1777-1792.
PMID: 35798920
Introduction: Biologic treatments are increasingly being used in the management of moderate to severe plaque psoriasis (PSO). Bimekizumab is a selective inhibitor of both interleukin (IL)-17A and IL-17F approved for...
4.
Leonardi C, Zhu B, Malatestinic W, Eastman W, Guo J, Murage M, et al.
Adv Ther
. 2022 May;
39(7):3214-3224.
PMID: 35570242
Introduction: Limited real-world data are available comparing multiple biologics on their adherence, persistence, and the use of concomitant biologics in the treatment of moderate-to-severe psoriasis in clinical practice. The objective...
5.
Lebwohl M, Leonardi C, Armstrong A, Rawnsley N, Alexander B, Goehring Jr E, et al.
Dermatol Ther
. 2021 Aug;
34(6):e15105.
PMID: 34418244
Brodalumab, an interleukin-17 receptor A antagonist, is approved for treatment of moderate-to-severe plaque psoriasis in adults without response or with loss of response to other systemic therapies. In the United...
6.
Leonardi C, Tao R, Setayeshgar S, Wang S, Burge R, Zhu B, et al.
J Dermatolog Treat
. 2021 Jul;
33(4):2278-2284.
PMID: 34236934
Objective: To assess treatment patterns of Ixekizumab (IXE) and evaluate the speed of onset and long-term clinical and quality-of-life outcomes among a subset of patients who switched from adalimumab (ADA)...
7.
Hawkes J, See K, Burge R, Strakbein S, McKean-Matthews M, Saure D, et al.
Dermatol Ther (Heidelb)
. 2021 May;
11(4):1107-1118.
PMID: 34050899
Introduction: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is an approved treatment for plaque psoriasis. This study aimed to use animated visualizations as a tool to simplify complex...
8.
Leonardi C, See K, Gallo G, McKean-Matthews M, Zhang Y, Goldblum O, et al.
Dermatol Ther (Heidelb)
. 2021 May;
11(4):1249-1263.
PMID: 34047947
Introduction: Psoriasis Area Severity Index (PASI) assessment is complex and time-consuming. A simpler assessment measure more sensitive to changes in symptom severity and predictive of patients' quality of life (Dermatology...
9.
Lebwohl M, Leonardi C, Wu J, Armstrong A, Rawnsley N, Merchant M, et al.
Dermatol Ther (Heidelb)
. 2020 Dec;
11(1):173-180.
PMID: 33337520
Introduction: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have...
10.
Lebwohl M, Leonardi C, Wu J, Yamauchi P, Rawnsley N, Merchant M, et al.
J Drugs Dermatol
. 2020 Aug;
19(8):807-808.
PMID: 32845586
No abstract available.